Naratriptan Hydrochloride Drug Due Diligence Report 2026

This Naratriptan Hydrochloride Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Naratriptan Hydrochloride can convert its Small molecule drug profile and Not disclosed biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Naratriptan Hydrochloride (query alias: naratriptan)
Modality / target	Small molecule drug; Not disclosed; Not disclosed
Highest global status	Approved
Originator	Not disclosed
Active developers	Not disclosed

The MCP disease footprint includes no disclosed indication. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-UMIN000061371	Phase 4	参加者募集終了‐試験継続中/No longer recruiting	20	内服２時間後の頭痛改善、頭痛消失と有害事象
NCT03066544	Phase 1/2	Unknown status	50	time to headache relief
JPRN-UMIN000050092	Not Applicable	Complete: follow-up complete	20	片頭痛発作開始後30分以内にトリプタン通常量を使用し、その１時間後に頭痛改善が50％未満であった場合に、Lasmiditan 50mgを追加投与する。Lasmiditan 50mgの内服は頭痛開始後1-1.5時間となる。Lasmiditan 50mgの内服後、１,２,４時間後の頭痛改善と有害事象などを患者自身が評価、記録する。頭痛とその改善はNRSとHIT-6を使用する。嘔気、過敏症状、日常生活支障度も評価する。

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Triptan Use and Discontinuation in a Representative Sample of Persons With Migraine: Results From Migraine in America Symptoms and Treatment (MAST) Study (P4.10-019)

Not Applicable; n=not disclosed; evaluation: not stated. Reported fields: Discontinuation rates = 66.5 % ; Discontinuation rates = 55.2 % ; Discontinuation rates = 81.5 %

A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan

Phase 4; n=60; evaluation: not stated. Reported fields: Workplace Productivity and Activity Impairment Scale (WPAI).(Mean): Mean Difference (Final Values) = -1.71(95% CI, -2.92 to -0.49), P-Value = 0.007; Workplace Productivity and Activity Impairment Scale (WPAI).(Mean) = 4.15 hours (95% Confidence Interval, 2.93 - 5.36); Workplace Productivity and Activity Impairment Scale (WPAI).(Mean): Mean Difference (Final Values) = -1.71(95% CI, -2.92 to -0.49), P-Value = 0.007

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Naratriptan Hydrochloride addresses its disclosed development indications. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 0 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
No matched asset transaction returned.

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO